KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Shares Outstanding (2018 - 2025)

Castle Biosciences' Shares Outstanding history spans 2 years, with the latest figure at $25.3 million for Q3 2021.

  • For Q1 2023, Shares Outstanding changed N/A year-over-year to $26.7 million; the TTM value through Mar 2023 reached $26.7 million, changed N/A, while the annual FY2022 figure was $26.6 million, 4.63% up from the prior year.
  • Shares Outstanding for Q1 2023 was $26.7 million at Castle Biosciences, up from $26.4 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $26.7 million in Q1 2023 and bottomed at $1.9 million in Q1 2019.
  • The 5-year median for Shares Outstanding is $25.0 million (2020), against an average of $19.8 million.
  • The largest annual shift saw Shares Outstanding surged 783.66% in 2020 before it increased 4.21% in 2022.
  • A 2-year view of Shares Outstanding shows it stood at $17.1 million in 2019, then skyrocketed by 47.61% to $25.3 million in 2021.
  • Per Business Quant, the three most recent readings for CSTL's Shares Outstanding are $26.7 million (Q1 2023), $26.4 million (Q3 2022), and $26.3 million (Q2 2022).